Fig. 1From: Alteration in TET1 as potential biomarker for immune checkpoint blockade in multiple cancersFlowchart of the clinical cohort consolidation. a. Consolidation of the discovery cohort from six published studies. b. Consolidation of the validation cohort and the non-ICI-treated cohort from Samstein et al. ICI, immune checkpoint inhibitor; HNSCC, head and neck squamous cell carcinoma; NSCLC, non-small-cell lung cancer; IRB, Institutional Review BoardBack to article page